Gilead Sciences Receives EU Marketing Approval for Trodelvy as Breast Cancer Treatment

MT Newswires Live06-23

Gilead Sciences (GILD) said Tuesday that Trodelvy has received marketing approval from the European Commission as first-line treatment for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.

The authorization is based on data from a phase 3 study that showed patients treated with Trodelvy achieved statistically significant progression-free survival compared with standard-of-care chemotherapy as a first-line treatment, Gilead said.

The company said it has submitted a supplemental filing to the European Medicines Agency for Trodelvy combined with Merck's (MRK) Keytruda for patients with PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer based on the phase 3 data.

The application is currently under review, Gilead added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment